Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5512452 | 0.99 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL14393481 | 0.89 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL14393479 | 0.87 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL5142144 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL5510297 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL5084526 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34864 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3277527 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34863 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10772550 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904434-A2 | HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007011594-A2 | HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF | WYETH (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070015828-A1 | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | WYETH (US) | 2007-01-18 | — | — | US | claimed |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | WYETH | 2008-10-23 | — | — | US | disclosed |
| EP-1904434-A2 | HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011594-A2 | HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF | WYETH (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011594-A2 | HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF | WYETH (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015828-A1 | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | WYETH (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015828-A1 | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | WYETH (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015828-A1 | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | WYETH (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015828-A1 | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 2/4885 |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | UGT1A4, SLC6A4, UGT1A3 | SLC6A2 5/4885SLC6A4 2/4885SLC6A3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.